European Society of Human Genetics reprimands Myriad on patent secrets

The European Society of Human Genetics policy committee has chastised Myriad Genetics for refusing to share its patented genetic database on the grounds that the information is commercially sensitive.

 While Myriad primarily uses its patented BRCA genetic test to look for cancer-causing mutations, it has also used the test to compile a database of “variants of unknown significance” which some scientists, activists and lawyers argue argue should be released because they could facilitate other research.

View the original article here: European Society of Human Genetics reprimands Myriad Genetics on patent secrets

Related on the SLP

Have patients been forgotten in the quest to build private BRCA variant databases? ACLU to Myriad Genetics: Patients, not companies, own personal genetic data

The heated debate over trans athletes in the WNBA

Viewpoint: Women, depression and empathy: Explaining the gender gap in views about child-murderer Lindsay Clancy

Outing students: California court says schools need not notify parents of their child’s gender identity—unless they ask